Don Rule

Don Rule

Don founded Translational Software® to accelerate the use of molecular diagnostics. Prior to this he had a 14 year career at Microsoft, holding a variety of roles in providing Internet access to MSN, pioneering Virtual Private Networking products, and integrating Instant Messaging with Voice Over IP networks. Don founded the BioIT Alliance from within Microsoft to accelerate collaboration in translational research.

Read recent posts by this author below »

What You Need To Know About These 3 Newly Approved Drug-Genome Interactions

In 2018, 59 new medications earned FDA approval. Multigene pharmacogenomics (PGx) panels can safely prescribe three of these new drugs to prevent unnecessary toxicities and drug-genome interactions. A decade ago,

Exploring the Knowledge and Perspectives of US Payers on Preemptive Pharmacogenetic Testing

When it comes to wide-scale adoption of pharmacogenomics (PGx) testing, reimbursement has been one of the industry’s biggest roadblocks. This is especially true when it comes to the preemptive testing model. While

A Global Perspective on Consumer and Healthcare Genomics

I was honored to be invited by Illumina to speak at their Consumer and Healthcare Genomics Summit in Bangkok on May 8. Illumina had assembled an eclectic group of their experienced customers as well as vendors that

How One Company Is Improving the Health and Wellness of Its Employees with PGx Testing

Translational Software is excited to be collaborating with Allscripts Healthcare Solutions, a leader in practice management and electronic health record technology. Under this new partnership, Translational Software

The Critical Differences Between DTC and Clinical PGx Tests

In November 2018, 23andMe became the first company authorized by the U.S. Food and Drug Administration (FDA) to offer direct-to-consumer pharmacogenomic reporting.  Pharmacogenomic reports use genetic testing to